by
Gus Iversen, Editor in Chief | June 18, 2015
From the June 2015 issue of HealthCare Business News magazine
Three particular radiopharmaceuticals that may not fit nicely into the current reimbursement model are: Indium, which is used for labeling white cell studies to look for infection; Octreoscan, which is done on rare neuroendocrine tumors; and DaTscan for Parkinson’s disease.
The SNMMI proposed to CMS that theyseparate radiopharmaceuticals out from the APC system and make new categories based on what types are used. “We’re concerned that the cost of new drugs coming down the line is probably going to be expensive and probably won’t fit in the current APC system,” says Dr. Gary Dillehay, the outgoing president of the SNMMI and professor of radiology at Northwestern Memorial Hospital in Chicago.
Ad Statistics
Times Displayed: 19605
Times Visited: 366 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The cost of tracers is influenced by many factors that are not always understood by the practicing physician. Among those factors, according to Dillehay, might be the expenses associated with getting through the FDA approval process.
Back to HCB News
